Homepage > Company > Media > Pharma News > 2018 > Trump urges U.S. Congress to back 'right to try' for terminally ill

Trump urges U.S. Congress to back 'right to try' for terminally ill

WASHINGTON (Reuters) - President Donald Trump said in his State of the Union address to the U.S. Congress on Tuesday that he wants lawmakers to support the “right to try” for terminally ill patients to try experimental therapies not approved by federal authorities.

“It is time for the Congress to give these wonderful Americans the ‘right to try,'” Trump said.

Legislation along these lines was approved by the Senate in August by a vote of 94-1. It was designed to give terminally ill patients access to unapproved medications and to provide immunity for physicians willing to administer the treatments.

Trump has expressed support for the measure before.

January 31, 2018

https://www.reuters.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...